Rapport Therapeutics ends S-3 stock prospectus

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. filed an 8-K stating that, effective September 8, 2025, it terminated the sales agreement prospectus tied to its Form S-3 registration statement (File No. 333-288444) for common stock sales through Leerink Partners LLC and Cantor Fitzgerald & Co.

The underlying Sales Agreement dated July 1, 2025 remains in full force and effect, but the company cannot sell common stock under it unless a new prospectus, prospectus supplement or new registration statement is filed. As of September 8, 2025, the company had not issued or sold any shares under this Sales Agreement.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rapport Therapeutics (RAPP) disclose in its latest 8-K?

Rapport Therapeutics disclosed that, effective September 8, 2025, it terminated the sales agreement prospectus related to its Form S-3 registration statement for common stock. The Sales Agreement itself continues, but no stock can be sold under it without a new prospectus or registration statement.

Does Rapport Therapeutics plan to sell common stock under the terminated prospectus?

Rapport Therapeutics will not sell common stock under the terminated sales agreement prospectus. Future sales under the existing Sales Agreement would require the company to file a new prospectus, a prospectus supplement, or a new registration statement before any shares could be issued.

Did Rapport Therapeutics (RAPP) sell any shares under the July 1, 2025 Sales Agreement?

As of September 8, 2025, Rapport Therapeutics had not issued or sold any shares of common stock under the July 1, 2025 Sales Agreement. The 8-K explicitly states that no shares were sold before the related sales agreement prospectus was terminated.

Is the Sales Agreement with Leerink Partners and Cantor Fitzgerald still in effect?

Yes. The 8-K states that, other than terminating the related prospectus, the Sales Agreement dated July 1, 2025 with Leerink Partners LLC and Cantor Fitzgerald & Co. remains in full force and effect, meaning the contractual framework is still active without a current prospectus.

What registration statement is affected for Rapport Therapeutics (RAPP)?

The terminated prospectus was filed with Rapport Therapeutics’ registration statement on Form S-3, File No. 333-288444. This change affects the company’s ability to issue common stock under that specific shelf registration until a new prospectus, supplement, or registration statement is filed.

What class of securities was covered by the terminated Rapport Therapeutics prospectus?

The terminated prospectus related to shares of Rapport Therapeutics’ common stock, par value $0.001 per share. These shares were issuable pursuant to the Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. before the company ended the associated prospectus.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/08/2025 - 04:02 PM EDT Learn about SEC filing dates

false 0002012593 0002012593 2025-09-08 2025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2025

Rapport Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-42121		88-0724208
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

99 High Street
Suite 2100
Boston, Massachusetts		02210
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 321-8020

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		RAPP		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Effective September 8, 2025, the Company terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333-288444) (the “Registration Statement”) and related to the shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), issuable pursuant to the Sales Agreement, dated July 1, 2025, by and among the Company, Leerink Partners LLC and Cantor Fitzgerald & Co. (the “Sales Agreement”). As a result, the Company will not make any sales of Common Stock pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect. As of September 8, 2025, the Company had not issued and sold any shares of Common Stock under the Sales Agreement.

A copy of the Sales Agreement was filed as Exhibit 1.2 to Registration Statement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Rapport Therapeutics, Inc.
Date: September 8, 2025				By:		/s/ Troy Ignelzi
						Troy Ignelzi Chief Financial Officer